News

Pursuant to the agreement Adapt has received from Lightlake a global license to develop and commercialize Lightlake’s intranasal naloxone opioid overdose reversal treatment. In exchange for licensing its

Its lead compound PPL-003 showed success in two studies in rabbits. In the first study, topical eye administration of PPL-003 at the highest feasible dose was well tolerated

PPD and ERT will work closely throughout all areas of the clinical development process to offer clients efficiencies through alignment of crucial aspects of service delivery, including budget

The Company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma,

As part of the deal, the two parties will jointly carry out the clinical proof of concept (PoC) trial of E6201, a dual-targeted FLT3 and MEK inhibitor for

As part of the deal, DURECT will receive an upfront fee of $2m in cash from Santen as well as reverie contingent cash payments upon the achievement of

Black fungus is known to benefit health issues associated with the lungs, stomach and liver in the Eastern culture. It is rich in iron, protein, vitamins, polysaccharide, fiber,

Following approval, rIX-FP will provide people with hemophilia B and their physicians a long-acting treatment option with dosing intervals up to 14 days. The BLA is based on

In the UK, venous thrombosis or blood clotting is a major cause of death and for those patients that survive PE and DVT, there can be long term